PremiumCompany AnnouncementsAlaunos Therapeutics Announces Executive Financial Leadership Changes Alaunos Therapeutics Regains Nasdaq Listing Compliance ZIOPHARM Oncology trading halted, news pending PremiumThe FlyLaidlaw downgrades Alaunos to Hold on ‘uncertain future’ Alaunos Therapeutics downgraded to Hold from Buy at Laidlaw Alaunos Therapeutics reports Q2 EPS (4c), consensus (4c) PremiumThe FlyPrecigen amends exclusive license agreement with Alaunos Therapeutics Alaunos Therapeutics appoints Hofmeister to board of directors Alaunos Therapeutics assumed with an Overweight at Wells Fargo